Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12992809 | 0.85 | TEAD3 (0.56) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL291194 | 0.82 | SMN1; SMN2 (0.57) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL3484952 | 0.82 | TEAD3 (0.46) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL2079376 | 0.81 | TSHR (0.50) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL27691549 | 0.80 | L3MBTL1 (0.42) | EPHX2TEAD3TSHRL3MBTL1TDP1 | |
| SCHEMBL3603037 | 0.79 | ALDH1A1 (0.52) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL22367410 | 0.79 | SMN1; SMN2 (0.53) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL24756824 | 0.79 | SMN1; SMN2 (0.53) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL543078 | 0.79 | ALDH1A1 (0.53) | EPHX2TEAD3TSHRHTTSMN1; SMN2 | |
| SCHEMBL13902888 | 0.79 | EPHX2 (0.53) | EPHX2TEAD3TSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353651-A1 | COMPOUNDS, DERIVATIVES, AND ANALOGS FOR CANCER | HYGIA PHARMACEUTICALS, LLC | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353651-A1 | COMPOUNDS, DERIVATIVES, AND ANALOGS FOR CANCER | KRAS, PIK3CA, PIK3CD | EPHX2 1698/4885TEAD3 1270/4885TSHR 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.